Radiotherapy Robotics & Positioning Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Radiotherapy Robotics & Positioning Market in 2026?

USD 1.4 billion in 2026 and USD 3.6 billion by 2036 at a 10.0% CAGR.

Demand for radiotherapy robotics & positioning is projected to push valuation from USD 1.4 billion in 2026 to USD 3.6 billion by 2036 at a 10.0% CAGR. Cancer caseloads are increasing the pressure on radiotherapy departments to deliver accurate treatment within fixed daily schedules. The National Cancer Institute reported in May 2025 that almost 20 million new cancer cases occurred worldwide during 2022. That volume supports investment in robotic delivery and positioning systems that can reduce repeated setup without widening safety margins. The broader radiotherapy device outlook explains why motion control and automated alignment carry more weight during equipment replacement.

Adoption differs between countries that replace established treatment fleets and countries that are building high-precision capacity. United States hospitals often assess robotic systems during replacement projects that build on established stereotactic workflows. Chinese hospitals are adding particle therapy and image-guided services through projects that need new positioning infrastructure. The National Cancer Institute reported in May 2025 that United States cancer care spending reached USD 208.9 billion in 2020. That cost base gives administrators a clear reason to compare throughput with retreatment risk during capital reviews. Facility planning links this market with hadron therapy systems through upright positioning that can remove a rotating gantry from selected room designs. This change can lower bunker requirements and alter the investment case for smaller treatment centers.

Summary of the Radiotherapy Robotics & Positioning Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Motion management and repeatable setup are shaping capital decisions across stereotactic programs that treat moving targets within narrow clinical margins and limited daily treatment slots. Robotic delivery can follow breathing-related motion and reduce wide treatment margins while preserving healthy tissue during selected body radiation plans. Automated positioning limits repeated couch corrections and helps departments protect daily capacity without extending operating hours across the full treatment schedule. High-dose schedules need dependable imaging and beam-hold controls, so hospitals increasingly review delivery hardware and positioning software as one clinical workflow. Replacement projects create limited value without medical physics staff who can commission the system and maintain daily verification throughout its service life.
Product and Segment View	Robotic beam delivery and patient positioning address different parts of the same treatment workflow, so segment value depends on how well they connect. Robotic radiosurgery systems is set to account for 38.0% of product revenue in 2026 through established use across intracranial and body stereotactic treatment. Intracranial radiosurgery is projected to represent 34.0% share in 2026 due to frequent imaging and noncoplanar delivery requirements. Systems are likely to hold 62.0% of component revenue in 2026 through the cost of delivery hardware plus imaging and positioning equipment. Planning integration increases software value by reducing information gaps between simulation and clinical treatment delivery across each treatment fraction.
Geography and Growth Outlook	Country growth depends on treatment capacity and the route used to approve new delivery or positioning systems. The United States is projected to grow at 10.0% CAGR by 2036 as an established treatment base enters replacement cycles. The European Union is estimated to record 9.5% CAGR through 2036 under national hospital budgets and common device requirements. Japan emphasizes precision upgrades, whereas India is adding treatment access through public hospitals and private oncology networks.
Competitive Landscape	Competition depends on connecting treatment planning and patient alignment with dependable motion control across each clinical radiation workflow and service continuity after installation. Accuray focus on CyberKnife delivery and Synchrony tracking for selected cranial and body targets across established service networks. Varian combines treatment delivery with positioning and oncology software across hospital networks that operate several treatment rooms during replacement cycles. Brainlab provides room-based monitoring that can work with third-party linear accelerators across mixed treatment rooms. C-RAD and Vision RT add surface-guided tracking that supports motion control throughout routine treatment delivery. Leo Cancer Care and RaySearch Laboratories support upright workflows whose progress depends on particle therapy projects and planning integration at fixed-beam centers.
Analyst Perspective	Commercial value depends on proving that robotic precision improves treatment capacity without overloading clinical teams with verification work. Cancer centers are expected to assess delivery and positioning as one investment since separate purchases can create integration work that slows commissioning. Managed service models may attract centers seeking predictable maintenance costs, although capital purchase remains the main model with 56.0% share in 2026. Greater automation increases dependence on commissioning and data quality, so vendors with practical medical physics support can reduce adoption risk. - Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI's proprietary forecasting model and primary research

How is the radiotherapy robotics & positioning market segmented?

The industry is segmented across product and application categories plus component and end user groups with business models and regions.

The market is divided into six segments that influence equipment selection and recurring revenue throughout a hospital investment cycle. Product analysis separates robotic radiosurgery systems from patient positioning and upright platforms according to delivery architecture. Application analysis covers intracranial radiosurgery and body stereotactic treatment together with conventional workflows and proton positioning. Component analysis distinguishes capital systems from planning software and services that create revenue after installation. End-user analysis compares cancer centers with university hospitals and private radiotherapy clinics according to purchasing needs. Business model analysis examines capital purchases alongside managed service and leasing arrangements that spread ownership costs. Regional analysis connects treatment capacity with regulation and facility readiness that influence installation timing across each country. This structure supports comparison with patient positioning accessories without treating accessories as complete robotic platforms.

What supports demand for robotic radiosurgery systems within the product category?

Robotic radiosurgery systems combine a compact linear accelerator with computer-controlled movement and repeated image checks during each treatment session. Accuray received NMPA approval in China for its CyberKnife S7 and Radixact SynC systems in January 2025. The company stated that China could require approximately 2,000 additional radiotherapy systems during the following five years. This approval shows that robotic delivery demand depends on regulatory access and treatment capacity.

• Based on product, robotic radiosurgery systems are forecast to represent 38.0% of revenue in 2026 through established use in stereotactic treatment. Noncoplanar beam paths and real-time tracking allow these systems to manage complex cranial and body cases within one platform.
• Radiation oncology departments are expected to compare robotic systems with fixed-gantry platforms according to treatment mix. The stereotactic radiation therapy category provides a useful benchmark for cases that need accurate setup across fewer fractions.

How does intracranial radiosurgery shape demand within the application category?

Small targeting errors can affect nearby brain structures, so intracranial radiosurgery needs tight geometric control throughout each treatment. The National Cancer Institute estimated in April 2025 that the United States would record 24,820 new brain and nervous system cancer cases during 2025. Specialist cranial workflows also treat metastatic lesions and selected benign disorders that do not appear in that primary cancer figure. The estimate identifies a measurable clinical base for systems that support accurate frameless treatment (National Cancer Institute, April 2025).

• In 2026, intracranial radiosurgery is forecast to represent 34.0% of application revenue through precise image registration and noncoplanar delivery. This workflow allows hospitals to treat selected lesions without open surgery while preserving a tightly controlled dose around sensitive structures. Commercial value depends on referral depth and specialist expertise that sustain regular case volumes throughout each year.
• Neurosurgical and radiation oncology teams are expected to favor integrated planning and positioning for complex cranial cases. The gamma knife systems category offers an adjacent benchmark for dedicated treatment and established referral patterns. Robotic platforms add frameless workflows together with treatment flexibility across selected body indications and treatment sites.

How are systems positioned within the component category?

Delivery and positioning systems shape room design and daily throughput across radiotherapy departments during routine clinical use. C-RAD reported in May 2025 that it had introduced Catalyst+ LITE at ESTRO for clinics beginning surface-guided radiation therapy. The platform gives clinics a simpler entry point while preserving a path toward broader motion-management features. The oncology imaging software category shows how image data moves from setup into treatment review. Compatibility across installed linear accelerators can lower integration risk during a positioning upgrade.

• By component, systems are estimated to hold 62.0% share in 2026 due to the cost of delivery equipment and imaging hardware. This position reflects the capital needed for a complete treatment room and the related installation work. Service planning starts during purchase review and continues through commissioning plus routine quality assurance across the full system life.
• Hospital networks are anticipated to spend more on software as several treatment rooms begin sharing planning and motion data. Integration quality can influence throughput and retraining costs across a multi-room program during routine clinical use.

What are the drivers, restraints, and opportunities in the radiotherapy robotics & positioning market?

Motion control is expected to support demand; capital and commissioning requirements may delay adoption; upright workflows are projected to widen facility options for space-constrained treatment centers.

• Driver: Motion management is expected to support robotic delivery for tumors affected by breathing and patient movement.
• Restraint: Regulatory quality-system requirements and clinical commissioning are anticipated to extend product launches and hospital purchasing schedules.
• Opportunity: Upright positioning is projected to reduce room design constraints and create new options for particle therapy centers.

Treatments affected by breathing or patient movement need active motion control throughout radiotherapy beam delivery. Vision RT announced in July 2025 that AlignRT 7.4 had received a CE mark with Elekta's integrated gating interface. The release combines automatic beam hold with motion detection across six directions, extending surface-guided positioning from setup assistance into active delivery control. The respiratory gating systems category provides an adjacent view of motion control for moving tumors. A tested beam-control interface can reduce commissioning risk during equipment upgrades.

The United States Food and Drug Administration reported in February 2026 that its Quality Management System Regulation became effective for medical device manufacturers. The rule incorporates ISO 13485:2016 into 21 CFR Part 820 and updates inspections for regulated devices. Radiotherapy robotics and positioning manufacturers need aligned design controls plus production records that support inspection. Hospitals must complete acceptance testing and local commissioning before clinical use begins at each treatment site. These requirements protect treatment quality but can extend the path from product launch to dependable revenue.

Upright positioning creates a commercial opening for centers that cannot accommodate a large rotating gantry. RaySearch released RayStation v2025 in May 2025 with support for treatment planning around Leo Cancer Care's upright platform. Clinical use requires completed planning models and collision checks for each new positioning geometry at the treatment site. Fixed-beam layouts can reduce room requirements across selected particle therapy projects that face space or construction limits. Clinical adoption still depends on evidence and payment for treatment services supported by the new geometry.

Which country CAGRs are profiled in the radiotherapy robotics & positioning market?

Country	CAGR
United States	10.0%
European Union	9.5%
Japan	9.0%

Source: FMI's proprietary forecasting model and primary research.

How do country-level CAGRs compare in the radiotherapy robotics & positioning market?

Country growth reflects different starting points in treatment capacity and different routes for approving capital equipment. Mature health systems focus on replacement and workflow integration across departments that already run complex stereotactic programs. Countries expanding cancer services place greater emphasis on new treatment infrastructure and specialist referral networks. Hospital budgets affect each country, although staffing and room availability change the value gained from robotic equipment. The medical physics services category offers a useful comparison for commissioning capacity across new installations in hospitals.

• United States adoption is shaped by an established stereotactic treatment base and regular replacement of aging radiation equipment. The market is projected to expand at 10.0% CAGR from 2026 to 2036, supported by demand for motion tracking and adaptive treatment workflows. In May 2025, the National Cancer Institute projected nearly 2.04 million new cancer cases in the United States for that year. This treatment burden supports investment in systems that can improve daily capacity without relaxing clinical quality controls. Cancer centers often compare software integration with service coverage during purchasing decisions for multi-room radiotherapy programs.
• European Union demand is anticipated to be driven by hospital capital cycles and common medical device requirements across national health systems. Radiotherapy robotics and positioning revenue is forecast to rise at 9.5% CAGR between 2026 and 2036 as hospitals modernize imaging and alignment. Data published by Eurostat in April 2026 showed 2,976 radiation therapy units across EU countries with available information for 2021. France accounted for 775 units and Italy reported 432 units within the same official dataset. Germany recorded another 398 units, showing that a multi-country installed base spans several national procurement systems. This distribution creates upgrade opportunities for vendors that can provide local clinical support and integration documentation across existing treatment rooms.
• Japan combines high-precision cancer care with careful technology evaluation across hospitals that manage concentrated referral volumes. Demand is estimated to advance at 9.0% CAGR by 2036, supported by continued renewal of stereotactic and image-guided treatment capacity. The February 2025 National Cancer Center overview recorded 1,636 new radiotherapy patients at its central hospital from April 2023 through March 2024. Its east hospital treated 2,000 new radiotherapy patients during the same reporting period at its specialist campus. Those volumes support investment in positioning and quality assurance systems that receive regular specialist use. Japanese hospitals are likely to favor products that fit established clinical protocols and provide dependable maintenance throughout the equipment life.

Who are the notable companies in the radiotherapy robotics & positioning market?

Notable companies include Accuray, Varian, Leo Cancer Care, Brainlab, C-RAD, RaySearch Laboratories, and Vision RT.

Competition spans robotic delivery and surface-guided positioning together with planning software that connects simulation with treatment. Accuray supplies CyberKnife for robotic stereotactic workflows, whereas Varian combines linear accelerators with positioning and oncology software. Brainlab provides room-based monitoring that can extend motion control across third-party treatment units (Brainlab AG, accessed July 2026). C-RAD and Vision RT add surface-guided tracking for departments that operate mixed equipment fleets across several treatment rooms. Leo Cancer Care and RaySearch Laboratories support upright treatment workflows for fixed-beam particle therapy centers. The oncology information systems category remains relevant to data continuity from planning through treatment review. Competitive strength depends on integration quality and service coverage throughout the full equipment life for hospitals.

• Accuray competes through CyberKnife robotic delivery and Synchrony tracking that adjusts the beam to patient or target motion. Cancer centers may favor the platform for frameless stereotactic programs that need cranial and body treatment flexibility within one dedicated robotic system across specialist referral programs.
• Varian combines treatment delivery with patient positioning and oncology software across hospital networks that operate several radiation rooms. Its portfolio can reduce interface work for organizations seeking consistent planning and alignment during capital replacement projects across multiple treatment sites within one service model.
• Brainlab and C-RAD provide room-based positioning or motion monitoring around linear accelerators from other manufacturers. Vision RT adds surface-guided tracking that can standardize motion control across mixed equipment fleets in hospitals. These approaches let hospitals improve accuracy without replacing the primary delivery unit during every capital review.
• Leo Cancer Care and RaySearch Laboratories connect upright positioning hardware with compatible planning models for particle therapy. Commercial progress depends on fixed-beam projects that need smaller room designs and dependable software support through commissioning and routine quality assurance across new treatment centers.

Competitive Benchmarking: Radiotherapy Robotics & Positioning Market

Company	Robotic Delivery	Patient Positioning	Motion Management	Planning Integration	Geographic Reach
Accuray	High	Medium	High	High	High
Varian	Medium	High	High	High	High
Leo Cancer Care	Low	High	Medium	Medium	Medium
Brainlab	Low	High	High	High	High
C-RAD	Low	High	High	Medium	High
RaySearch Laboratories	Low	Medium	Medium	High	High
Vision RT	Low	High	High	Medium	High

Scoring basis: Ratings compare verified product capability within the exact market together with the availability of integration support. High indicates broad direct capability across the defined market, whereas Medium reflects partial capability or partner dependence. Low indicates limited direct capability within the same market category or treatment workflow for the company.

Source: Official product pages and corporate releases from Accuray, Varian, Leo Cancer Care, Brainlab, C-RAD, RaySearch Laboratories, and Vision RT, accessed July 2026.

Key Developments in the Radiotherapy Robotics & Positioning Market

• In July 2025, Leo Cancer Care received FDA 510(k) clearance for the Marie upright radiotherapy platform. Marie combines upright patient positioning with computed tomography for particle therapy planning and verification across fixed-beam treatment rooms. The clearance gives United States centers a regulated route to evaluate smaller room designs through an upright workflow.
• In September 2025, Accuray introduced the Stellar configuration of its Radixact treatment delivery system at the ASTRO annual meeting. The package adds image guidance and surface-guided treatment to adaptive workflow options across several radiation therapy indications.
• In September 2025, Varian announced Halcyon updates that included the PerfectKinetix Dynamic Couch and planned IDENTIFY motion monitoring integration. The company linked these features to faster alignment and automated beam control across high-volume treatment schedules. Selected capabilities remained subject to regulatory clearance at launch, limiting immediate availability across some markets.
• In February 2026, Vision RT launched AlignRT Core as a modular surface-guided radiation therapy platform with three-camera tracking and couch-move vector output. The platform supports active motion management through software modules that can expand its clinical use after installation.

Key Players in the Radiotherapy Robotics & Positioning Market

Robotic Delivery Platforms

• Accuray Incorporated
• Varian Medical Systems, Inc.

Patient Positioning and Motion Management

• Leo Cancer Care, Inc.
• Brainlab AG
• C-RAD AB
• Vision RT Ltd.

Treatment Planning and Workflow Integration

• RaySearch Laboratories AB

Radiotherapy Robotics & Positioning Market - Report Scope

Coverage field	Report scope
Market breakdown	Product, application, component, end user, business model, and region.
Market Definition	Robotic radiotherapy delivery and patient positioning systems that automate beam movement or patient alignment for external beam treatment.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
Countries Covered	United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, South Korea, India, Australia, New Zealand, GCC countries, South Africa, and Türkiye.
Key Companies Profiled	Accuray, Varian as a Siemens Healthineers company, Leo Cancer Care, Brainlab, C-RAD, RaySearch Laboratories, and Vision RT.
Forecast Period	2026 to 2036.
Approach	Hybrid supply-led and demand-led market sizing supported by primary interviews and official desk research sources.

Source: FMI’s proprietary forecasting model and primary research.

Radiotherapy Robotics & Positioning Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: FMI's proprietary forecasting model and primary research.

Radiotherapy Robotics & Positioning Market by Segments

Radiotherapy Robotics & Positioning Market segmented by Product:

• Robotic Radiosurgery Systems
• Robotic Patient Positioning Platforms
• Imaging-Guided Robotic Delivery Systems
• Upright Positioning Platforms

Radiotherapy Robotics & Positioning Market segmented by Application:

• Intracranial Radiosurgery
• Spine and Body Stereotactic Body Radiotherapy
• Conventional Radiotherapy Positioning
• Proton Therapy Positioning

Radiotherapy Robotics & Positioning Market segmented by Component:

• Systems
• Treatment Planning Software
• Positioning and Motion Software
• Services

Radiotherapy Robotics & Positioning Market segmented by End User:

• Cancer Centers
• University Hospitals
• Private Radiotherapy Clinics

Radiotherapy Robotics & Positioning Market segmented by Business Model:

• Capital Purchase
• Managed Service
• Lease
• Software and Hardware Upgrades

Radiotherapy Robotics & Positioning Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Rest of Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia
  • India
  • Rest of South Asia
• Oceania
  • Australia
  • New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Rest of Middle East and Africa

Research Sources and Bibliography

• Accuray Incorporated. (2025, January 13). Accuray announces China NMPA approval of Radixact SynC and CyberKnife S7 systems.
• Accuray Incorporated. (2025, September 26). Accuray launches all-in-one radiotherapy solution with advanced capabilities.
• Brainlab AG. (n.d.). ExacTrac Dynamic: SRS and SBRT positioning with surface and X-ray tracking.
• C-RAD AB. (2025, May 7). Solid quarter in a wait-and-see market.
• European Commission, Eurostat. (2026, April 24). Cancer statistics.
• Leo Cancer Care. (2025, July 26). Leo Cancer Care receives FDA 510(k) clearance for Marie.
• National Cancer Center Japan. (2025, February). National Cancer Center overview.
• National Cancer Institute. (2025, April 15). Brain cancer specialized programs of research excellence.
• National Cancer Institute. (2025, May 7). Cancer statistics.
• RaySearch Laboratories AB. (2025, May 2). RaySearch releases RayStation v2025.
• Shanghai Municipal Government. (2026, January 14). Shanghai cancer center plans expansion to boost particle therapy capacity.
• Siemens Healthineers Cancer Care. (2025, September 28). Varian elevates Halcyon platform by redefining the patient experience.
• Soni, S., Sharma, A. K., Sundaram, V., & Katoch, C. D. S. (2025, March 21). Establishing a radiation oncology department in India: Key challenges and essential considerations from the perspective of radiation oncology professionals. Reports of Practical Oncology and Radiotherapy, 30(1), 114-121.
• United States Food and Drug Administration. (2026, February 2). Quality Management System Regulation.
• Vision RT Ltd. (2025, July 16). Vision RT certified with Elekta's integrated gating interface: AlignRT 7.4 gains CE mark.
• Vision RT Ltd. (2026, February 25). Vision RT introduces AlignRT Core, a flexible approach to SGRT adoption.

This bibliography is provided for reader reference and uses primary government, standards-body, official trade body, and company sources.

This Report Answers

• What is the estimated value of the radiotherapy robotics and positioning market in 2026?
• How is the market projected to change between 2026 and 2036?
• Which product and application segments account for the reported revenue shares?
• How do robotic delivery systems differ from patient positioning platforms?
• Which country growth rates are compared across the forecast period?
• What operational factors influence hospital purchasing and commissioning decisions?
• Which verified companies provide delivery, positioning, or planning capability?
• How are upright treatment workflows changing facility design choices?
• What evidence supports the driver, restraint, and opportunity assessment?
• Which capabilities determine competitive positioning across the defined market?